Altana launches ReQuest for GERD patients

30 October 2006

German drugmaker Altana AG has launched ReQuest, a new symptom questionnaire for gastroesophageal reflux disease patients to complete in order to provide clinicians with a robust understanding of their symptoms, enable categorization according to the severity of their condition and use this information to make an accurate assessment of their treatment outcome.

According to the firm, data presented at the 14th United European Gastroenterology Week congress, held in Berlin, Germany, show that, to optimize attainment of complete remission, the duration of treatment should be tailored according to the severity of initial esophagitis. Treatment for 12 weeks is necessary to achieve complete remission in patients who have more severe grades of esophagitis.

Altana noted that the comprehensive symptom evaluation using ReQuest, in combination with endoscopy, is being used in current large-scale international trials, which aim to identify how treatment can be tailored and response predicted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight